» Articles » PMID: 18041046

Post-exposure Prophylaxis with a Maraviroc-containing Regimen After Occupational Exposure to a Multi-resistant HIV-infected Source Person

Overview
Journal J Med Virol
Specialty Microbiology
Date 2007 Nov 28
PMID 18041046
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

We report the case of a health care worker who received a post-exposure prophylaxis including an investigational drug, maraviroc, after a needle stick percutaneous injury to an HIV-infected patient with late-stage disease and harboring a multi-drug resistant virus. Post-exposure prophylaxis including maraviroc was pursued for a total of 28 days, with a weekly clinical and biological evaluation. Post-exposure prophylaxis was well tolerated, with no increase in liver function tests. The health care worker remained HIV-negative after a 6-month follow-up.

Citing Articles

Maraviroc: a review of its use in HIV infection and beyond.

Woollard S, Kanmogne G Drug Des Devel Ther. 2015; 9:5447-68.

PMID: 26491256 PMC: 4598208. DOI: 10.2147/DDDT.S90580.


Local phylogenetic analysis identifies distinct trends in transmitted HIV drug resistance: implications for public health interventions.

Brooks J, Niznick H, Ofner M, Merks H, Angel J BMC Infect Dis. 2013; 13:509.

PMID: 24171696 PMC: 3816547. DOI: 10.1186/1471-2334-13-509.


Clinical use of CCR5 inhibitors in HIV and beyond.

Gilliam B, Riedel D, Redfield R J Transl Med. 2011; 9 Suppl 1:S9.

PMID: 21284908 PMC: 3105509. DOI: 10.1186/1479-5876-9-S1-S9.